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ABSTRACT  
 
Objective: The purpose of this study was to test for moderating effects of patient characteristics 
on self-management interventions developed to address symptoms during cancer treatment. 
Patient’s age, education and depressive symptomatology were considered as potential 
moderators. 
 
Methods: A secondary analysis of data of 782 patients from two randomized clinical trials was 
performed. Both trials enrolled patients with solid tumors undergoing chemotherapy. After 
completing baseline interviews, patients were randomized to a nurse-delivered intervention 
versus intervention delivered by a “coach” in trial I, and to a nurse-delivered intervention   
versus an intervention delivered by an automated voice response system in trial II. In each of the 
two trials, following a 6-contact 8-week intervention, patients were interviewed at week 10 to 
assess the primary outcome of symptom severity.  
 
Results: While nurse-delivered intervention proved no better than the “coach” or automated 
system in lowering symptom severity, important differences in the intervention by age were 
found in both trials. Patients <45 years responded better to the “coach” or automated system; 
while those >75 years favored the nurse.  Education and depressive symptomatology did not 
modify the intervention effects in either of the two trials. Depressive symptomatology had a 
significant main effect on symptom severity at week 10 in both trials (p=.03 and p<.01, 
respectively). Education was not associated with symptom severity over and above age and 
depressive symptomatology. 
 
Conclusions: Clinicians need to carefully consider the age of the population when using or 
testing interventions to manage symptoms among cancer patients.  
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INTRODUCTION 
Targeting interventions to characteristics of specific groups of patients has been 
supported in research studies and frequently discussed as desirable.  While a positive finding of 
efficacy or effectiveness of an intervention provides evidence base for clinical practice, a 
negative finding could result from differing effects of the intervention on subgroups of the 
population.  Thus, in addition to the overall comparison of an intervention to usual care or 
another intervention, it is important to test for moderating effects to identify potential efficacy 
for subgroups of the population [1]. The examination of moderating effects of patient 
characteristics on intervention efficacy is fraught with difficulty [2,3].  Post hoc tests for 
characteristics, such as age, may lack discrimination because distributions are skewed toward 
older ages. This is especially true in those with cancer, as the majority is diagnosed at an older 
age [4,5]. Further, by design, most trials are powered to detect main effects but underpowered to 
detect the differential effects of the intervention by patient characteristics. Even when 
moderating effects are observed, it is unlikely that similarly constructed samples are available for 
replication. Thus, moderating effects are seldom tested, and as a result, are not incorporated into 
the inclusion criteria or used as stratification or minimization variables in randomized trials [3]. 
This paper focuses on two large trials of self-care interventions aiming to manage cancer 
patients’ symptoms during chemotherapy. The purpose of this work was to test for the 
moderating effects of patients’ characteristics in each trial and then to compare the findings from 
the two trials. The similarity between the two trials provided a unique opportunity to determine 
whether moderating effects can be replicated. 
The nurse-delivered symptom management intervention common to the two trials was 
developed based on the principles of cognitive behavioral therapy [6,7].  Nurses helped patients 
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isolate symptom-related problems and taught patients how to assume control for solving these 
problems and how to use symptom management strategies so that they fit in patient’s daily lives 
[8]. The nurse-delivered intervention, which included both cognitive-behavioral and educational 
elements, was compared to the educational interventions in both trials. The education 
intervention implemented as the second arm in each of the two trials involved referral of the 
patients to a written guide that contained information on symptom management strategies. In 
Trial I, this educational intervention was delivered by a non-nurse “coach,” and in Trial II, the 
educational intervention was delivered by an automated telephone system. The two trials 
enrolled similar samples of patients and incorporated the same self-management intervention 
delivered by a nurse in one of the arms, and the same educational intervention in the other arm 
(with different modes of delivery in two trials). Patient characteristics tested as potential 
moderators were selected based on the literature reviewed below and included age, education, 
and depressive symptomatology. 
With few exceptions [9-12], findings indicate that interventions that incorporate cognitive 
behavioral approaches are equal to, or in some cases, superior to other psychological 
interventions [13-16].  Combinations of cognitive behavioral and educational strategies have 
demonstrated effectiveness at reducing symptom severity from side effects of cancer treatment 
[17,18].  
The literature on moderating effects for symptom management interventions in chronic 
diseases including cancer has mixed findings. A meta-analysis of insomnia trials indicated that 
adults who were 55 years of age and older responded to cognitive behavioral strategies more 
favorably in terms of sleep efficiency and total sleep time when compared to adults less than 55 
years of age [19]. Conversely, a study examining cognitive behavioral intervention for symptom 
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management of patients with advanced cancer found older age reduced the effectiveness of the 
intervention [17] Another study found that age did not modify the effect of the behavioral 
intervention on symptom severity [12]. Evaluations of possible moderating effects of education 
are limited. Education moderated individuals’ responses to attitude measurement [20,21]; and 
influenced women’s responses to genetic counseling and testing for breast/ovarian cancer [22].  
Depressive symptoms in cancer patients are widely studied across numerous primary and 
specialty care settings [23].  For most cancer patients these symptoms are not sufficiently severe 
to warrant a full clinical diagnosis of depression [24,25].  Research with cancer patients who do 
not meet the criteria for a clear diagnosis of clinical depression are summarized as depressive 
symptoms. Data from several meta-analyses, and our own past trials, suggests that cognitive 
behavioral and educational strategies can influence cancer- and treatment-related symptoms as 
well as depressive symptoms [26-30].  There is strong evidence that chronic diseases increase 
patient depressive symptoms, but few investigations exist about the possible moderating effects 
of depressive symptomatology on cancer patients’ responses to interventions for symptom 
management [31].  A Cochrane review [32] and a meta-analysis of 6 trials [33] demonstrate the 
effectiveness of both cognitive behavioral and educational interventions on depressive affect in 
patients with cancer, suggesting possible mediation but not necessarily moderating effects of 
depressive affect in symptom management in cancer.   
In summary, interventions that incorporate cognitive behavioral and/or educational 
strategies can assist patients with different chronic diseases to manage their symptoms. Some 
evidence indicates that age, education, and depressive affect may moderate the impact of these 
interventions on symptom severity; however, none of the existing studies have attempted to 
replicate moderating effects of these patient characteristics across similarly designed trials. This 
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report fills this gap by presenting the secondary analyses of each of the two completed and 
similarly designed symptom management trials. The research question of moderating effects of 
age, education, and depressive symptomatology is answered for each trial, and the findings are 
compared to assess their replication from one trial to the other. 
METHODS 
Below we describe the two trials and summarize the published findings that were based 
on the analyses of additive effects of trial arms following the intent to treat principles [17,18].  
Setting and Sample  
Enrollment for the original trials occurred at two comprehensive cancer centers, two 
community cancer oncology programs, and five hospital affiliated community oncology centers. 
Institutional review board approvals were obtained from each site. Registered nurses from these 
sites implemented the recruitment protocol. To be eligible for either trial, patients met the 
following inclusion criteria: 21 years of age or older, a diagnosis of a solid tumor or non-
Hodgkin’s lymphoma, undergoing intravenous chemotherapy, able to speak and read English, 
having a touchtone phone, and without hearing deficits. Based on our prior results, following 
consent and prior to enrollment, each trial used a specific symptom severity criteria that used a 
scale ranging from 0 (no symptom) to 10 (worst possible) [18].  Patients scoring a severity of 
two on pain and fatigue or a three on pain or fatigue and who had a family caregiver entered 
Trial I. Patients scoring a two or higher on any symptom entered Trial II. All but 2 patients who 
completed screening entered either Trial I or Trial II [34].  The two patients who never reached a 
two in severity on any symptom were sent a letter thanking them for their participation and no 
further interviews were conducted. Figure 1 summarizes the flow of patients in both trials.  
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Trial Arms 
All arms of the trials were delivered entirely by phone with nurse-delivered symptom 
management intervention implemented as an arm in each trial. In Trial I, a 6-contact 8-week 
nurse-delivered self-management intervention was compared with a 6-contact 8-week 
educational intervention delivered by a non-nurse “coach.” In Trial II, a 6-contact 8-week nurse 
delivered self-management intervention was compared with a 6-contact 8-week automated voice 
response (AVR) system. During each of 8  telephone contacts spread over 10 weeks (conducted 
by nurse, “coach,” or AVR,  respectively), the severity of 16 symptoms (fatigue, pain, dyspnea, 
insomnia, anxiety, depression, nausea/vomiting, difficulty remembering, dry mouth, poor 
appetite , numbness and tingling, diarrhea, cough, constipation, weakness, and alopecia) was 
rated by patients  using the scale from 0 (no symptom) to 10 (worst possible).  If a patient rated 
any symptom at a severity of 4 or higher (threshold) at any contact, they received management 
strategies [35].  
For symptoms at 4 or higher, the “coach” in Trial I and the AVR in Trial II referred the 
patient to a section of a written Symptom Management Toolkit (SMT), which has been proven 
effective in several trials [8,18,36] to assist in managing the symptoms. This printed SMT, which 
was developed and refined through previous studies, was written at the 6th grade level and 
contained evidence-based self-care strategies specific to each symptom [31,37].  Each symptom 
was presented in an identical format of frequently asked questions: what the symptom is, how 
people describe it, the causes of the symptom including medications, and a set of strategies 
presented in short points for managing the symptom. At contacts 2-6, the “coach” or the AVR 
asked the patient if they read the section of the SMT, and if so, how successful it was for 
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managing symptoms reported at the last contact. Patients who did not read assigned sections of 
the SMT, or who rated it unsuccessful, were encouraged to read the section again and continue to  
 
follow the strategies. Thus, the content of the educational interventions delivered by the “coach” 
and AVR was identical, only mode of delivery differed. In contrast to these two targeted 
approaches of referral to the SMT, the nurse arms of the trials offered more specific approaches 
to symptom management based on patients’ responses, in addition to the referral to SMT. Nurses 
worked in partnership with the patients on prioritizing which symptoms experienced by patients 
should be addressed. Then, nurses used a drop-down list of strategies (specific and relevant to 
each symptom) on their computer screen to select strategies for the management of selected 
symptoms. The list of strategies that could be delivered by nurses was broader than the list in the 
SMT and could include nurses’ clinical judgment.  Symptom management strategies delivered 
by nurses were organized into four domains: teaching (adherence to medications, prioritizing, 
limiting daily tasks), prescribing (diet, exercise, lifestyle changes), counseling and support 
(coping strategies, reframing), and communicating with healthcare providers (how to report 
problems, prepare for appointments, ask for help). According to the nurse intervention protocol, 
up to four strategies could be delivered for each symptom at each phone contact.  At contacts 2-
6, nurses asked patients if they had tried the previously suggested interventions, and if so, how 
successful it was for managing the symptom. Interventions not tried or unsuccessful were 
replaced with new ones, and a suggestion was made to continue the successful interventions.  
Measures 
Age, sex (male or female), site of cancer (breast, prostate, lung, colon, or Hodgkin’s 
Lymphoma), stage of cancer (I—IV) and comorbidities were obtained from the patients’ medical 
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records. Based on the distribution of age and its non-linear relationship with symptom severity, 
age was grouped into five categories: 45 years or younger, 46 to 55 years, 56 to 65 years, 66 to 
75 years, and older than 75 years of age. Patients’ educational levels were collapsed into three 
categories: high school or less, more than high school to completed college, and graduate or 
professional education. The Center for Epidemiological Studies- Depression [38], a 20 item 
reliable valid instrument with responses assessed on four-point scale (0-3), a range of 0 to 60, 
was used to assess depressive symptomatology during intake. Although not designed for clinical 
diagnosis due to relatively low specificity, the score of 16 is an established highly sensitive 
screening cut-off for clinical depression [38,39],  and for analysis, the CESD variable was 
dichotomized as less than 16 versus 16 or higher. The Symptom Experience Inventory, developed 
in past studies by Given et al. [35,40,41] (internal consistency reliability of .79), was used to 
assess symptom severity during screening, baseline interview, the six intervention contacts, and 
10 week interview. The severity of each symptom was rated from 0 (no symptom) to 10 (worst 
possible), and severity scores were summed across the 16 symptoms to create an index of 
severity ranging from 0 to 160 [17].  The symptom list from the interviews differed slightly from 
the list from the six intervention contacts. During the interviews, nausea and vomiting were 
separated into 2 items, and a single item of depression asked during the intervention contacts was 
replaced with the CESD for a more detailed assessment of depressive symptoms.   
Previous results from the two trials 
In both trials I and II, no differences in summed symptom severity were found between 
the trial arms in the intent-to-treat analyses [18,42].  All four intervention arms had significant 
improvements in symptom severity over baseline [43].  Per protocol analyses revealed 
differences in patient subgroups and success with the management of specific symptoms. First, 
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nurses were more successful than the AVR in retaining lung cancer patients and managing their 
symptoms [18].  When compared with patients in the nurse arm of Trial II, patients in the AVR 
arm had a better response to the management of anxiety, depression, poor appetite, cough and 
fatigue. In Trial II, nurses were more successful than the AVR in managing cancer pain [36]. 
These findings are from intent-to-treat and per protocol analyses that included the main effect of 
trial arm variable within each trial, but no interaction terms. This paper extends the completed 
primary analyses to include tests of moderating effects of the patient characteristics based on the 
significance of the interactions of trial arm variable with patient characteristics. While both trials 
were powered to detect main effects of the moderate size, neither trial was formally powered to 
detect these interactions. We draw upon the similarity of the design of the two trials to assess if 
any evidence of moderating effects in one trial is replicated in the other one. 
Data Analyses 
Since separate randomization procedures were carried out for each trial, the analyses of 
data from each trial were performed separately and the results compared. Descriptive statistics 
for the demographic, outcome and potential moderator variables were obtained. The baseline 
differences between the groups in each of the trials were evaluated using chi-square and t-tests. 
Attrition analyses were conducted to examine the baseline characteristics of patients who 
dropped out between baseline and week 10 and were compared by trial arm according to the 
potential moderators.  
To determine if age, education, or depressive affect moderated the impact of the 
interventions on symptom severity, the criteria established by Baron and Kenny [2] and Kraemer 
et al. [3] were followed.  Age, education, and depressive symptomatology were evaluated at 
baseline to determine if they had a main effect on symptom severity at week 10 and if there was 
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a significant interaction between each potential moderator variable and intervention arm variable. 
Least squares (LS) means, also known as adjusted means of symptom severity, were calculated 
according to the interaction terms. Further, the moderating effect of age in both trials was tested 
in the presence of depressive symptoms and education variables as main effects and in the 
interaction with intervention arm to evaluate if the effect of age persisted after adjusting for the 
level of education and depressive symptomatology.  P-values in tables are reported without 
adjustments for multiple comparisons. When LS means for multiple age groups were compared 
by intervention arm, conclusions about significance were made using Bonferroni correction. For 
example, when five age groups were tested, a significance was indicated by p<.01 instead of 
p<.05 to control the overall probability of type I error. All analyses were performed using SAS 
version 9.3. 
 
RESULTS 
 Table 1 summarizes the socio-demographic information, sites and stages of cancer for 
each arm of the two trials. Table 2 provides the means and standard deviations of symptom 
severity and CESD scores at intake.  Baseline equivalence was achieved between the arms for 
the two trials. When baseline scores were compared for cases lost versus those retained at week 
10 with respect to age, education, depressive symptomatology, and symptom severity, no 
differences were found between arms within trials. Thus, any moderating effects are unlikely to 
be confounded by differential attrition between arms. Figure 1 displays the flow of patients 
through the two trials.  At intake, all patients were undergoing chemotherapy, as this was one of 
the inclusion criteria. At week 10, in trial I, 51% of the patients in the nurse arm and 58% in the 
“coach” arm remained in treatment (p=.38 for arm difference). The corresponding figures for 
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trial II were 58% for the nurse arm and 59% for AVR (p=.88). Thus, symptom severity at week 
10 did not differ by treatment status (ongoing versus completed or stopped) in either trial. After 
adjusting for symptom severity at baseline for each trial, there was no significant difference for 
symptom severity at week 10 and there were no main effects for age or education in either trial.  
Depressive symptoms at baseline were significantly associated with symptom severity at week 
10 in both trials (p=.03 and p<.01, respectively, see Table 3). When testing for moderating 
effects, age by group interactions were not significant for trial I but were significant for trial II 
(see Table 3), due to the smaller sample size of trial I. 
Examining the adjusted means for symptom severity by age at week 10 revealed a 
remarkably similar pattern with the differences in the age categories for the trials (see Table 4). 
Among patients 45 years of age or younger, the self-care strategies delivered by the AVR were 
more successful than the intervention delivered by the nurse in lowering symptom severity at the 
10 week assessment (p<.01).  The comparison of the “coach” versus nurse arm in Trial I showed 
a similar relationship between LS means, but the difference did not reach statistical significance. 
LS means of symptom severity in trial I were 29.28 for the nurse arm and 19.16 for the “coach” 
arm, and in trial II, 30.39 for the nurse arm and 15.63 for the AVR arm at week 10. The pattern 
of LS means reverses for patients 75 and older compared to younger patients in both trials. In 
trial I, the LS means of symptom severity at week 10 were 18.04 for the nurse arm and 34.67 for 
the “coach” arm, and in trial II, 19.84 for the nurse arm and 26.35 for the AVR arm. Even though 
the magnitude of the differences between LS means by arm were similar for the two trials, the 
differences in sample sizes (see Table 1) resulted in the LS means being statistically significant 
for trial II but not trial I. In the middle-aged categories, 46-55, 55-65, and 66-75, both arms in 
each trial appear to be equally successful.   
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Tests for the moderating effects of education and depressive symptoms by arm revealed no 
associations with symptom severity at the 10-week end point. Education had neither a main nor 
moderating effect, and depressive symptoms had a main effect on symptom severity at week 10 
but did not moderate the effects of the interventions. The LS means by age and arm listed in 
Table 3 did not change after adjusting for education and depressive symptoms and are not 
presented. Thus, the moderating effect of age on patient response to the trial arms is not 
influenced by education or depressive symptoms, and the observed effects for age are not 
artifacts of educational attainment.  
 
DISCUSSION 
 Findings from these two trials contribute important information about differential effects 
of the interventions and the need to select the best performing interventions for specific patient 
subgroups. A carefully constructed intervention delivered by specially trained nurses was 
compared against an interpersonal “coach” and an AVR with referral to a SMT. When data from 
all patients were analyzed according to the intent-to-treat principle, an elaborate nurse-delivered 
symptom management intervention fared no better than streamlined approaches, where patients 
were directed to follow specific written directions on their symptoms that were assessed above a 
severity threshold. When several patient characteristics were examined in relation to the 
intervention effect, only age showed evidence of modifying the effects of interventions. In the 
assessment of moderating effects of age, several limitations deserve notice. First, in both trials 
the numbers of patients in the youngest and oldest age groups were relatively small. Second, we 
obtained these findings using age as a categorical variable. After evaluating alternatives, we used 
categories that best fit the data because the effect of age was non-linear. Finally, our sample had 
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a large proportion of women and relatively low proportion of minorities, reflective of the 
population of patients treated at the participating oncology clinics. Despite these limitations, the 
core strength of our argument regarding the moderating effects of age relies on the fact that the 
patterns of differences according to age were the same across separate but very similarly 
constructed trials, each designed to address a common endpoint.   
The nurse-delivered intervention required an average of 54 minutes per contact while the 
AVR required only 20 minutes, and the associated costs per contact were around $60 for the 
nurse arm and $17 for the AVR arm [43].  However, time and costs are not the only 
considerations in developing a symptom management intervention. If patients do not accept the 
intervention, then it is of little value. Further, certain subgroups of the patient population may 
benefit from a more extensive intervention, while other subgroups would do just as well with a 
simpler intervention. Answering the question about moderating effect is key to selecting the best 
interventions that tailor to patient characteristics, and ultimately to the development of more 
effective therapeutic approaches [1].  
As Kraemer and colleagues have argued, moderating effects can be disguised [3 ].  A 
difficulty with moderating effects is that formal hypotheses are seldom presented and trials are 
rarely powered to test for moderating effects. As such, arguments to explain the moderating 
effects are largely post hoc and seldom flow from the conceptual framework upon which the trial 
is based. While no main effects were observed for the intervention arm, the difference existed in 
the patient’s age in Trial II, and a similar pattern toward significance was observed in Trial I. 
Younger patients responded to educational approaches delivered by the AVR or a “coach” and 
older patients to nurse-delivered symptom management strategies. New strategies were presented 
in response to new symptoms that rose above threshold at successive contacts. Our evidence 
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reveals that younger patients appeared able to identify specific strategies from the SMT and to 
incorporate them into their daily lives resulting in improved symptom management.  The oldest 
group of patients may, based on some evidence, possess less attention control and adaptability 
[44,45].  Therefore, they may value interactions with nurses who assist them to select and tailor 
interventions that address their symptoms in a manner that conforms to their daily schedules. The 
oldest patients in the “coach” or the AVR system, who were referred to the written guide, 
appeared less able to extract information and apply it to their personal situation to manage 
symptoms. In contrast, the youngest patients responded more favorably to classic written 
material that guided them to self-management approaches they could read and implement.  
Further supporting the similarity of the effects of age in the two trials is the fact that the 
nurse, “coach,” and AVR arms were tested on very similar samples of cancer patients 
undergoing chemotherapy. The significant age by trial arm interaction in Trial II and similar 
patterns in the adjusted means by trial arm and age in both trials strongly support the argument 
that older patients prefer the intervention utilizing interpersonal interactions with a nurse as 
compared to interactions with the AVR or a “coach” who refer them to a SMT. This difference 
may be based on the tailoring and support that nurses provide to older patients. In contrast, the 
younger patients may prefer approaches that allow them to read and act on information in their 
own styles. They may not want to invest the time or engage in extended conversations with 
nurses. They appear equally responsive to both the “coach” and the AVR because these arms 
drove the symptom severity lower than in the nurse arm. This suggests that their responsiveness 
is not due to a greater comfort with technology (there was no technology in the “coach” arm) but 
due to the relative simplicity of the intervention where symptoms were assessed, symptoms 
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above threshold were specified, and information was provided to the patients to draw upon as 
needed to manage symptoms. 
We saw no differences in the numbers of symptoms reported by the oldest and youngest 
age groups, so it is unlikely that the educational approaches worked better for persons with fewer 
symptoms to manage. Further, even though Trial I required that patients report pain and/or 
fatigue at a specified severity and have a participating family caregiver in order to enroll, we 
found no differences in average number of symptoms between the two trials.  Fatigue was the 
most prevalent symptom among all arms and pain while a bit higher in Trial I did not produce 
unique effects.  Participation of a family caregiver with the patient in Trial I but not in Trial II 
may have impacted the outcomes.  However, given the similar findings we believe such impacts 
are modest. The written strategies presented in the SMT were carefully measured so that reading 
and comprehension were at a 6th grade level.  We believe this may have helped reduce the effect 
of educational level on use of the SMT and allowed us to identify the moderating effects of age 
and not of education.  
 Finally, we found that higher levels of patients’ depressive symptoms at intake resulted in 
poorer symptom management at week 10, regardless of the intervention arm. Thus, given a 
standard dose of the intervention in either arm, patients with CESD scores of 16 or higher 
responded less favorably than those with scores below 16.  This appears consistent with reports 
by Given and colleagues [31], who indicated that patients with worse depressive symptoms 
required more contacts in order to respond to symptom management interventions. 
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Table Legends 
1. Table 1:  Baseline descriptive statistics by trial arm for the two trials 
2. Table 2:  Descriptive statistics for symptom severity and Center for Epidemiologic 
Studies – Depression (CESD) scores at intake and week 10 by trial arm for the two trials 
3. Table 3:  Summary of the model relating symptom severity at week 10 to severity at 
baseline, trial arm, and patient characteristics  
4. Table 4:  Least square means symptom severity at week 10, by age category and trial 
arm, adjusted for baseline severity and depressive affect 
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Table 1:  Descriptive statistics by trial arm for the two trials 
 Trial I  Trial II 
 
Nurse 
N = 115 
N (%) 
“Coach” 
N = 119 
N (%) 
 
Nurse  
N = 218 
N (%) 
AVR 
N = 219 
N (%) 
Age      
 45 12 (10) 16 (13) 
 
40 (18) 33 (15) 
46-55 32 (28) 30 (25) 56 (26) 68 (31) 
56-65 38 (33) 41 (34) 72 (33) 69 (32) 
66-75 27 (23) 20 (17) 36 (17) 27 (12) 
> 75 6 (5) 12 (10)         14 (6) 21 (10) 
Sex      
Male 47 (41) 47 (39) 
 
57 (26) 53 (24) 
Female 68 (59) 72 (61) 161 (74)       166 (76) 
Race      
Caucasian 99 (88)       110 (92) 
 
      186 (86)       184 (86) 
African American         10 (9) 7 (6) 27 (12) 22 (10) 
Others 4 (3) 2 (2) 4 (2) 8 (4) 
Education      
 High School 38 (33) 45 (38) 
 
71 (33) 67 (31) 
> High School -  
 College 
56 (49) 55 (46) 113 (52) 108 (49) 
Graduate/ 
Professional 
21 (18) 19 (16) 34 (16) 44 (20) 
Marital Status      
Never Married 7 (6) 13 (11) 
 
23 (11) 26 (12) 
Married/Living 
Together 
94 (82) 85 (72)       138 (63) 131 (59) 
Divorced/ 
Separated/ 
Widowed 
14 (12) 20 (17) 57 (26) 62 (29) 
Employed      
Yes 31 (27) 30 (25)  67 (31) 74 (34) 
No         84 (73)  89 (75)           151 (69)     145 (66) 
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Table 1 (Continued):  Descriptive statistics by trial arm for the two trials 
 Trial I  Trial II 
 
Nurse 
N = 115 
N (%) 
“Coach” 
N = 119 
N (%) 
 
Nurse  
N = 218 
N (%) 
AVR 
N = 219 
N (%) 
Cancer Site      
Breast 27 (23) 30 (25) 
 
90 (41) 87 (40) 
Colon        10 (9) 8 (7) 30 (14) 32 (15) 
Lung 34 (30) 35 (29) 37 (17) 34 (16) 
Genitourinary 13 (11)         10 (8)         13 (6)         15 (7) 
Gastrointestinal 
including pancreas 
6 (6) 16 (13) 16 (7)         16 (7) 
Other 25 (22) 20 (17)  32 (15) 35 (16) 
Cancer Stage      
Early 8 (7) 13 (11) 
 
31 (14) 44 (20) 
Late 105 (93) 104 (89)       185 (86) 175 (80) 
Metastasis      
Yes 75 (65) 69 (58) 
 
      128 (59) 112 (51) 
No 40 (35) 50 (42) 90 (41) 107 (49) 
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Table 2:  Descriptive statistics for symptom severity and Center for Epidemiologic Studies – 
Depression (CESD) scores at intake and week 10 by trial arm for the two trials 
  
 Trial I  Trial II 
 Nurse “Coach”  Nurse AVR 
 
Intake 
N = 
115 
Week 
10 
N = 89 
Intake 
N = 
119 
Week 
10 
N = 85  
Intake 
N = 
218 
Week 
10 
N = 
183 
Intake 
N = 
219 
Week 
10 
N = 
177 
Symptom Severity 
Mean (SD) 
39.9 
(21.0) 
21.3 
(17.9) 
39.2 
(22.9) 
21.0 
(16.6) 
 32.5 
(20.9) 
20.9 
(19.1) 
36.1 
(22.8) 
20.9 
(17.9) 
CESD 
Mean (SD) 
12.9 
(6.3) 
9.7 
(5.6) 
14.1 
(7.5) 
10.4 
(6.7) 
 12.3 
(7.7) 
10.0 
(7.3) 
12.9 
(8.0) 
9.5 
(6.5) 
      
 
 
 
Table 3:  Summary of the model relating symptom severity at week 10 to severity at baseline, 
trial arm, and patient characteristics.  
 
 Trial I  Trial II 
Source DF 
Type III 
SS 
Mean 
Square 
F 
Value 
Pr > 
F 
 Type III 
SS 
Mean 
Square 
F 
Value 
Pr > 
F 
Symptom 
severity at 
baseline 
1 5197 5197 20.62 <0.01 
 
19451 19451 83.50 <0.01 
Trial arm 1 35 35 0.14 0.71  26 26 0.11 0.74 
CESD 1 1284 1284 5.09 0.03  1909 1909 8.19 <0.01 
Age category 4 1089 272 1.08 0.37  521 130 0.56 0.69 
Age category  
Trial arm 
4 1169 292 1.16 0.33 
 
3658 914 3.93 <0.01 
F (11, 151) = 4.02, p < 0.0001  F(11,348) = 16.42, p < 0.0001 
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Table 4:  Least square means symptom severity at week 10, by age category and trial arm, 
adjusted for baseline severity and depressive affect. 
 Least Square Means from final model 
 Trial I  Trial II 
Age 
groups 
Nurse 
    N       Mean 
“Coach” 
    N       Mean    
p-
Value 
 
Nurse 
     N         Mean    
AVR 
   N         Mean 
p-Value 
 45 12 29.28 16 19.16 0.15  32 30.39 27 15.63 <0.01 
46-55 29 19.67 28 16.86 0.57  52 20.52 57 20.34 0.98 
56-65 35 19.83 37 22.83 0.49  61 22.51 57 21.50 0.72 
66-75 24 25.17 20 24.71 0.93  27 20.72 18 26.78 0.19 
> 75 4 18.04 12 34.67 0.19  11 19.84 18 26.35 0.27 
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